Company Interview / Not so Little Green Pharma

Paul Long CEO of Little Green Pharma (ASX:LGP) reports record revenue of over $10 million, fuelled by robust European growth and their first positive cash flow. Little Green Pharma's success stems from steady increases in Australia and significant orders in Germany, Denmark, and the UK.

Paul sees continued opportunities for growth with a strong position in the fast-growing Australian market and emerging European markets. The German market, in particular, shows potential for increased demand due to recent regulatory changes, positioning the company favourably.

Operational efficiencies remain a focus for Little Green Pharma (ASX:LGP) to enhance cash flow positivity. The company's strategic edge is further strengthened by Thorney Investment raising its stake. Paul emphasizes growth prospects in both mature markets and exciting new sectors like psychedelics.